Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -377.06 Thousand AUD | 98.01% |
| 2023 | -7.31 Million AUD | 33.94% |
| 2022 | -11.07 Million AUD | 46.47% |
| 2021 | -20.69 Million AUD | -50.73% |
| 2020 | -13.73 Million AUD | -544.19% |
| 2019 | -2.13 Million AUD | 61.15% |
| 2018 | -5.48 Million AUD | 50.06% |
| 2017 | -10.98 Million AUD | 1.71% |
| 2016 | -11.17 Million AUD | 38.96% |
| 2015 | -18.31 Million AUD | -5472.35% |
| 2014 | -328.7 Thousand AUD | 80.9% |
| 2013 | -1.72 Million AUD | 80.62% |
| 2012 | -8.88 Million AUD | -76.35% |
| 2011 | -5.03 Million AUD | -72.28% |
| 2010 | -2.92 Million AUD | 68.34% |
| 2009 | -9.23 Million AUD | 26.99% |
| 2008 | -12.64 Million AUD | -12.6% |
| 2007 | -11.23 Million AUD | -19.27% |
| 2006 | -9.41 Million AUD | 44.46% |
| 2005 | -16.95 Million AUD | -59.94% |
| 2004 | -10.6 Million AUD | -81.92% |
| 2003 | -5.82 Million AUD | 18.6% |
| 2002 | -7.16 Million AUD | -1260.52% |
| 2001 | -526.29 Thousand AUD | 57.19% |
| 2000 | -1.22 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.34 Million AUD | 0.0% |
| 2024 Q1 | -3.64 Million AUD | 50.19% |
| 2024 FY | -145.41 Thousand AUD | 98.01% |
| 2024 Q4 | -377.06 Thousand AUD | 0.0% |
| 2024 Q3 | -377.06 Thousand AUD | 88.73% |
| 2023 Q3 | -7.62 Million USD | -71.94% |
| 2023 Q4 | -7.31 Million AUD | 3.98% |
| 2023 FY | -7.31 Million AUD | 33.94% |
| 2023 Q1 | -4.71 Million USD | 57.43% |
| 2023 Q2 | -4.43 Million AUD | 6.02% |
| 2022 FY | -11.07 Million AUD | 46.47% |
| 2022 Q2 | -13.39 Million AUD | 0.59% |
| 2022 Q3 | -11.34 Million AUD | 15.31% |
| 2022 Q4 | -11.07 Million AUD | 2.33% |
| 2022 Q1 | -13.47 Million AUD | 34.9% |
| 2021 Q3 | -20.87 Million AUD | -29.93% |
| 2021 Q1 | -16.31 Million AUD | -18.83% |
| 2021 Q2 | -16.06 Million AUD | 1.54% |
| 2021 FY | -20.69 Million AUD | -50.73% |
| 2021 Q4 | -20.69 Million AUD | 0.86% |
| 2020 FY | -13.73 Million AUD | -544.19% |
| 2020 Q1 | -3.13 Million AUD | -47.29% |
| 2020 Q2 | -2.91 Million AUD | 7.16% |
| 2020 Q3 | -13.97 Million AUD | -379.36% |
| 2020 Q4 | -13.73 Million AUD | 1.72% |
| 2019 Q2 | -3.23 Million AUD | 0.0% |
| 2019 Q3 | -2.13 Million AUD | 34.1% |
| 2019 Q1 | -3.23 Million AUD | 41.05% |
| 2019 Q4 | -2.13 Million AUD | 0.0% |
| 2019 FY | -2.13 Million AUD | 61.15% |
| 2018 Q2 | -7.59 Million AUD | 0.0% |
| 2018 FY | -5.48 Million AUD | 50.06% |
| 2018 Q4 | -5.48 Million AUD | 0.0% |
| 2018 Q3 | -5.48 Million AUD | 27.74% |
| 2018 Q1 | -7.59 Million AUD | 30.89% |
| 2017 Q2 | -15 Million AUD | 0.0% |
| 2017 FY | -10.98 Million AUD | 1.71% |
| 2017 Q4 | -10.98 Million AUD | 0.0% |
| 2017 Q3 | -10.98 Million AUD | 26.75% |
| 2017 Q1 | -15 Million AUD | -34.19% |
| 2016 Q3 | -11.17 Million AUD | 23.0% |
| 2016 FY | -11.17 Million AUD | 38.96% |
| 2016 Q1 | -14.51 Million AUD | 20.73% |
| 2016 Q4 | -11.17 Million AUD | 0.0% |
| 2016 Q2 | -14.51 Million AUD | 0.0% |
| 2015 Q3 | -18.31 Million AUD | -8233.66% |
| 2015 FY | -18.31 Million AUD | -5472.35% |
| 2015 Q2 | 225.19 Thousand AUD | 0.0% |
| 2015 Q4 | -18.31 Million AUD | 0.0% |
| 2015 Q1 | 225.19 Thousand AUD | 168.51% |
| 2014 Q3 | -328.7 Thousand AUD | 88.52% |
| 2014 FY | -328.7 Thousand AUD | 80.9% |
| 2014 Q2 | -2.86 Million AUD | 0.0% |
| 2014 Q1 | -2.86 Million AUD | -66.37% |
| 2014 Q4 | -328.7 Thousand AUD | 0.0% |
| 2013 Q3 | -1.72 Million AUD | 71.02% |
| 2013 Q1 | -5.93 Million AUD | 33.16% |
| 2013 Q4 | -1.72 Million AUD | 0.0% |
| 2013 FY | -1.72 Million AUD | 80.62% |
| 2013 Q2 | -5.94 Million AUD | -0.05% |
| 2012 Q2 | -12.54 Million AUD | 0.0% |
| 2012 FY | -8.88 Million AUD | -76.35% |
| 2012 Q4 | -8.88 Million AUD | 0.0% |
| 2011 Q4 | -5.03 Million AUD | 0.0% |
| 2011 FY | -5.03 Million AUD | -72.28% |
| 2011 Q2 | -8.16 Million AUD | 0.0% |
| 2010 Q4 | -2.92 Million AUD | 0.0% |
| 2010 FY | -2.92 Million AUD | 68.34% |
| 2010 Q2 | -5.06 Million AUD | 0.0% |
| 2009 Q4 | -7.45 Million AUD | 0.0% |
| 2009 FY | -9.23 Million AUD | 26.99% |
| 2009 Q2 | -10.28 Million AUD | 0.0% |
| 2008 FY | -12.64 Million AUD | -12.6% |
| 2008 Q4 | -12.64 Million AUD | 0.0% |
| 2008 Q2 | -13.6 Million AUD | 0.0% |
| 2007 Q4 | -11.23 Million AUD | 0.0% |
| 2007 FY | -11.23 Million AUD | -19.27% |
| 2007 Q2 | -8.74 Million AUD | 0.0% |
| 2006 Q4 | -9.41 Million AUD | 0.0% |
| 2006 Q2 | -15.71 Million AUD | 0.0% |
| 2006 FY | -9.41 Million AUD | 44.46% |
| 2005 Q4 | -16.95 Million AUD | 0.0% |
| 2005 FY | -16.95 Million AUD | -59.94% |
| 2005 Q2 | -10.16 Million AUD | 0.0% |
| 2004 FY | -10.6 Million AUD | -81.92% |
| 2003 FY | -5.82 Million AUD | 18.6% |
| 2002 FY | -7.16 Million AUD | -1260.52% |
| 2001 FY | -526.29 Thousand AUD | 57.19% |
| 2000 FY | -1.22 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bionano Genomics, Inc. | 34.88 Million USD | 101.081% |
| iSpecimen Inc. | -2.14 Million USD | 82.441% |
| Prenetics Global Limited | -43.33 Million USD | 99.13% |
| OpGen, Inc. | 11.89 Million USD | 103.171% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.019% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 97.541% |
| CareDx, Inc | -47.97 Million USD | 99.214% |
| Exagen Inc. | -12.77 Million USD | 97.048% |
| Inotiv, Inc. | 382.14 Million USD | 100.099% |
| Guardant Health, Inc. | 220.22 Million USD | 100.171% |
| Biodesix, Inc. | 34.3 Million USD | 101.099% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 93.494% |
| Precipio, Inc. | -386 Thousand USD | 2.316% |
| Aspira Women's Health Inc. | -331 Thousand USD | -13.916% |
| Standard BioTools Inc. | 46.5 Million USD | 100.811% |
| 23andMe Holding Co. | -141.37 Million USD | 99.733% |
| Castle Biosciences, Inc. | -83.53 Million USD | 99.549% |
| Personalis, Inc. | -8.02 Million USD | 95.3% |
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 99.044% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 93.624% |
| T2 Biosystems, Inc. | 33.8 Million USD | 101.115% |
| Neogen Corporation | 735.62 Million USD | 100.051% |
| Natera, Inc. | -200.1 Million USD | 99.812% |
| Myriad Genetics, Inc. | 88.1 Million USD | 100.428% |
| ICON Public Limited Company | 3.56 Billion USD | 100.011% |
| NeoGenomics, Inc. | 269.19 Million USD | 100.14% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 97.541% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 100.076% |
| RadNet, Inc. | 1.14 Billion USD | 100.033% |
| MDxHealth SA | 18.88 Million USD | 101.997% |
| Check-Cap Ltd. | -24.75 Million USD | 98.477% |
| Twist Bioscience Corporation | -192.4 Million USD | 99.804% |
| Psychemedics Corporation | 334 Thousand USD | 212.893% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 99.543% |
| Sera Prognostics, Inc. | -2.02 Million USD | 81.352% |
| OPKO Health, Inc. | 230.68 Million USD | 100.163% |
| Illumina, Inc. | 1.21 Billion USD | 100.031% |
| DarioHealth Corp. | -7.54 Million USD | 95.004% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 84.543% |
| Medpace Holdings, Inc. | -103.32 Million USD | 99.635% |
| Prenetics Global Limited | -43.33 Million USD | 99.13% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 93.059% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 207.777% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 69.663% |
| Trinity Biotech plc | 63.73 Million USD | 100.592% |
| Neuronetics, Inc. | 2.79 Million USD | 113.481% |
| Sotera Health Company | 2.02 Billion USD | 100.019% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 69.663% |